SIC 2835
In Vitro & In Vivo Diagnostic Substances
16 companies · 1 with disclosed financials
Total revenue (latest)
$3.21B
Total net income
$811.3M
Avg net margin
25.2%
Median net margin
25.2%
5-year industry trend
Total revenue summed across 16 companies in the most recent fiscal year. Median margin is the cross-sectional median per year.
Largest by revenue
- 1IDXXIDEXX LABORATORIES INC /DE
$44.12B cap · 25.2% margin · as of 2025-09-30
$3.21B
revenue
- 2CLDXCelldex Therapeutics, Inc.
$2.43B cap
—
revenue
- 3NEOGNEOGEN CORP
$1.94B cap
—
revenue
- 4TKNOAlpha Teknova, Inc.
—
revenue
- 5IMDXInsight Molecular Diagnostics Inc.
$189.9M cap
—
revenue
- 6AWHLAspira Women's Health Inc.
—
revenue
- 7CDIOCardio Diagnostics Holdings, Inc.
$4.8M cap
—
revenue
- 8LNTHLantheus Holdings, Inc.
$6.05B cap
—
revenue
- 9ICCCIMMUCELL CORP /DE/
$90.1M cap
—
revenue
- 10BMRABIOMERICA INC
$7.3M cap
—
revenue
- 11NTLAIntellia Therapeutics, Inc.
$1.76B cap
—
revenue
- 12BZYRBURZYNSKI RESEARCH INSTITUTE INC
—
revenue
- 13QDELQuidelOrtho Corp
—
revenue
- 14QCLSQ/C TECHNOLOGIES, INC.
—
revenue
- 15ACHVACHIEVE LIFE SCIENCES, INC.
$481.5M cap
—
revenue
- 16VNRXVOLITIONRX LTD
$26.1M cap
—
revenue
Insider activity in this industry · last 12 months
Insider buying
$10.5M
Insider selling
$465.0M
Net flow
−$454.5M
Distinct insiders
55
Open-market trades summed across all 9 companies in the industry where insiders bought. Sales counted across all companies regardless. Filed via SEC Form 4.
Recently filed in this industry
Related industries
Pharmaceutical Preparations
SIC 2834 · 75 cos
Biological Products, (No Diagnostic Substances)
SIC 2836 · 25 cos
Industrial Organic Chemicals
SIC 2860 · 5 cos
Chemicals & Allied Products
SIC 2800 · 4 cos
Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)
SIC 2820 · 2 cos
Plastic Materials, Synth Resins & Nonvulcan Elastomers
SIC 2821 · 2 cos
Miscellaneous Chemical Products
SIC 2890 · 2 cos
Agricultural Chemicals
SIC 2870 · 1 cos
About the In Vitro & In Vivo Diagnostic Substances industry on ActaClear
ActaClear tracks 16 US-listed public companies classified under SEC SIC code 2835 (In Vitro & In Vivo Diagnostic Substances). Combined latest-period revenue across the sector is $3.21B, with a median net margin of 25.2% per company.
Every name on this page links to a full company dashboard with 5-year SEC financials, live market data, ratios, AI-summarised business description, insider transactions, and institutional ownership. Data is sourced directly from SEC EDGAR XBRL filings and refreshed continuously.